

January 7, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 15365-edited.doc).



Title: Severe Severe Henoch-Schönlein purpura with infliximab for ulcerative colitis

Author: Yang Song, Yan-Hong Shi, Chong He, Chang-Qin Liu, Jun-Shan Wang, Yu-Jie Zhao, Yan-Min Guo, Rui-Jin Wu, Xiao-Yue Feng, Zhan-Ju Liu

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 15365

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) More previous studies were added in the introduction part to demonstrate the efficacy of IFX, including clinical remission for short-term and long-term efficacy, the incidence of colectomy for IFX and placebo. Reported cutaneous complications were also listed following etanercept, adalimumab, and IFX.

(2) More information about the patient was clarified in the case report part, including her family history, allergic history, and marital history. Family history revealed nothing for both her parents and children. Allergic history was negative for any specific medication or food. She was married and gave birth to a daughter and a son at the ages of 23 and 25, respectively.

(3) The typographical errors in the article were corrected.

(4) More information about medications, including the factory and the country that manufactures the medication, and the prescribed dose was elaborated in the case report part. For example, she received enemas of mesalamine (4.0 g q.d.; Salofalk), diosmectite (6.0 g q.d.; Smecta; Beaufour-Ipsen Pharmaceutical Co. Ltd., Tianjin, China) and ethamsylate (0.5 g q.d.; Tianjin Jinyao Amino Acid Co. Ltd., Tianjin, China) but hematochezia persisted.

(5) In the edited manuscript, the particularity of our case was added in the discussion part. Our case is an old woman who has been diagnosed of UC for 5 years. She had severe Henoch-Schönlein purpura during her IFX management, with extensive ecchymosis and complicated medical history. Besides, the clinical significance of adverse effects was also added.

(6) Our manuscript has been edited by designated by Jing-Yun Ma Expert Group for SCI Biomedical Editing and Publishing. We believe the language of our manuscript has reached Grade A.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink that reads 'Yang Song'.

Yang Song, MD
Dept. of Gastroenterology
The Shanghai Tenth People's Hospital
Tongji University
Shanghai 200072
China
E-mail: 2013_songyang@tongji.edu.cn